# Candel Therapeutics Inc. (CADL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.78, market value $978 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Candel Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 7823.3×**. Each dollar of revenue is priced at 7823.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 7.7×**. The shares trade at 7.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -5.9%** (5-yr avg -36.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -73.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 40.5%**. Return on all capital, debt included, is 40.5%: comfortably above what that capital costs.
- **Return on assets: -15.0%**. Each dollar of assets produces -15.0% of profit.

## Growth
- **EPS growth (1 yr): 58.6%**. Earnings per share rose 58.6%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 3.5×**. It would take 3.5 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: -20.3×**. Operating profit covers interest only -20.3×: fragile.

## Dividends
- **Dividend: none**. Candel Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Candel Therapeutics Inc.; the consensus is strong_buy, with an average price target of $21.00 (+64% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 161.1%** (YTD 126.2%, 3-mo 50.2%). The shares are up 161.1% over twelve months including dividends.
- **From 52-week high: -8.7%** (193.8% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 1.94** (volatility 72%). Beta of 1.94 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CADL · Page: https://foliofundamentals.com/stocks/cadl

Not investment advice.